CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
+14.42%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$95.7M
AUM Growth
+$95.7M
(+13%)
Cap. Flow
+$7.12M
Cap. Flow
% of AUM
7.44%
Top 10 Holdings %
Top 10 Hldgs %
68.16%
Holding
32
New
6
Increased
8
Reduced
9
Closed
7
Top Buys
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$5.39M |
| 2 |
Evolent Health
EVH
|
$4.6M |
| 3 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
$3.61M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$2.06M |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
$1.68M |
Top Sells
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$3.67M |
| 2 |
Editas Medicine
EDIT
|
$2.95M |
| 3 |
EPZM
Epizyme, Inc
EPZM
|
$2.1M |
| 4 |
DexCom
DXCM
|
$1.98M |
| 5 |
GHDX
Genomic Health, Inc.
GHDX
|
$1.36M |
Sector Composition
| 1 | Healthcare | 83.76% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ONCE
1
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $8.31M | 8.27% | 162,500 -7,500 | -4% | -$383K |
|
2
Agios Pharmaceuticals
AGIO
$2.19B
| $7.86M | 7.82% | 187,500 +39,500 | +27% | +$1.65M |
|
|
FMI
3
DELISTED
Foundation Medicine, Inc.
FMI
| $7.28M | 7.24% | 390,000 +55,000 | +16% | +$1.03M |
|
|
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $7.13M | 7.1% | 430,000 +325,000 | +310% | +$5.39M |
|
|
LOXO
5
DELISTED
Loxo Oncology, Inc
LOXO
| $6.95M | 6.92% | 300,000 +50,000 | +20% | +$1.16M |
|
|
BPMC
6
DELISTED
Blueprint Medicines
BPMC
| $6.89M | 6.85% | 340,000 +18,700 | +6% | +$379K |
|
|
SAGE
7
DELISTED
Sage Therapeutics
SAGE
| $6.89M | 6.85% | 228,500 +39,500 | +21% | +$1.19M |
|
|
BLUE
8
DELISTED
bluebird bio
BLUE
| $5.3M | 5.28% | 122,500 +2,500 | +2% | +$108K |
|
|
9
Evolent Health
EVH
$1.12B
| $4.6M | 4.58% | +239,500 | New | +$4.6M |
|
10
Alnylam Pharmaceuticals
ALNY
$58.5B
| $4.02M | 4% | 72,500 -17,500 | -19% | -$971K |
|
|
KITE
11
DELISTED
Kite Pharma, Inc.
KITE
| $3.63M | 3.61% | 72,500 -2,500 | -3% | -$125K |
|
|
GNMK
12
DELISTED
GenMark Diagnostics, Inc
GNMK
| $3.61M | 3.59% | +415,000 | New | +$3.61M |
|
13
Voyager Therapeutics
VYGR
$186M
| $3.54M | 3.53% | 322,500 -16,862 | -5% | -$185K |
|
|
EPZM
14
DELISTED
Epizyme, Inc
EPZM
| $3.48M | 3.47% | 340,000 -205,000 | -38% | -$2.1M |
|
15
CytomX Therapeutics
CTMX
$336M
| $2.39M | 2.38% | 234,179 -86,844 | -27% | -$887K |
|
|
MYOK
16
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $2.22M | 2.21% | 179,029 -296,321 | -62% | -$3.67M |
|
|
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
| $2.06M | 2.05% | +150,000 | New | +$2.06M |
|
|
RXDX
18
DELISTED
Ignyta, Inc.
RXDX
| $2.03M | 2.02% | 375,000 +265,000 | +241% | +$1.44M |
|
|
AVXS
19
DELISTED
AveXis, Inc. Common Stock
AVXS
| $1.71M | 1.7% | 45,000 -18,000 | -29% | -$684K |
|
|
TSRO
20
DELISTED
TESARO, Inc.
TSRO
| $1.68M | 1.67% | +20,000 | New | +$1.68M |
|
21
Bristol-Myers Squibb
BMY
$96B
| $1.55M | 1.54% | 21,000 | – | – |
|
|
22
DexCom
DXCM
$29.5B
| $1.19M | 1.18% | 15,000 -25,000 | -63% | -$1.98M |
|
|
SYRS
23
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $908K | 0.9% | +50,000 | New | +$908K |
|
|
GNMX
24
DELISTED
Aevi Genomic Medicine, Inc.
GNMX
| $472K | 0.47% | +85,000 | New | +$472K |
|
25
Biogen
BIIB
$19.4B
| – | – | -5,000 | Closed | -$1.3M |
|